Sandoz Inc.'s proposed copies of Crexont infringe 12 patents for the Parkinson’s disease treatment, two Amneal Pharmaceuticals Inc. units said in the first federal infringement lawsuit over the drug since its September launch.
The Sandoz Group AG subsidiary’s generic versions of Crexont’s extended-release capsules infringe 10 patents held by Amneal’s Impax Laboratories LLC unit that expire in October 2034 and two owned by Amneal Pharmaceuticals LLC that expire in December 2041, according to a complaint filed Tuesday in the US District Court for the District of New Jersey.
- US Patent Nos. 11,986,449 and 12,109,185—whose 2041 expirations are the latest ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.